Amphiregulin Promotes Resistance to Gefitinib in NonSmall Cell Lung Cancer Cells by Regulating Ku70 Acetylation
Open Access
- 1 March 2010
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (3) , 536-543
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Acetylation of non-histone proteins modulates cellular signalling at multiple levelsThe International Journal of Biochemistry & Cell Biology, 2009
- Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase InhibitorsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- HATs and HDACs: from structure, function and regulation to novel strategies for therapy and preventionOncogene, 2007
- VorinostatNature Reviews Drug Discovery, 2007
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non–Small Cell Lung CancersCancer Research, 2005
- Cooperation of Amphiregulin and Insulin-like Growth Factor-1 Inhibits Bax- and Bad-mediated Apoptosis via a Protein Kinase C-dependent Pathway in Non-small Cell Lung Cancer CellsJournal of Biological Chemistry, 2005
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Ku Autoantigen: A Multifunctional DNA-Binding ProteinCritical Reviews in Biochemistry and Molecular Biology, 2000
- Bid-induced Conformational Change of Bax Is Responsible for Mitochondrial Cytochrome c Release during ApoptosisJournal of Cell Biology, 1999